nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP2E1—lung cancer	0.496	1	CbGaD
Methotrimeprazine—Necrotizing enterocolitis—Paclitaxel—lung cancer	0.0179	0.0925	CcSEcCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Paclitaxel—lung cancer	0.0179	0.0925	CcSEcCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Docetaxel—lung cancer	0.0152	0.0784	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Docetaxel—lung cancer	0.0152	0.0784	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Paclitaxel—lung cancer	0.0147	0.0757	CcSEcCtD
Methotrimeprazine—CYP2D6—Gefitinib—lung cancer	0.014	0.19	CbGbCtD
Methotrimeprazine—CYP2E1—Etoposide—lung cancer	0.0125	0.171	CbGbCtD
Methotrimeprazine—Necrotising colitis—Docetaxel—lung cancer	0.0124	0.0642	CcSEcCtD
Methotrimeprazine—CYP2D6—Vinorelbine—lung cancer	0.0108	0.146	CbGbCtD
Methotrimeprazine—CYP1A2—Erlotinib—lung cancer	0.01	0.136	CbGbCtD
Methotrimeprazine—CYP2D6—Erlotinib—lung cancer	0.00826	0.112	CbGbCtD
Methotrimeprazine—HTR2A—phrenic nerve—lung cancer	0.00794	0.312	CbGeAlD
Methotrimeprazine—Necrotising colitis—Doxorubicin—lung cancer	0.00776	0.04	CcSEcCtD
Methotrimeprazine—Sudden death—Teniposide—lung cancer	0.00775	0.04	CcSEcCtD
Methotrimeprazine—CYP1A2—Etoposide—lung cancer	0.00725	0.0986	CbGbCtD
Methotrimeprazine—CYP2D6—Vinblastine—lung cancer	0.00663	0.0902	CbGbCtD
Methotrimeprazine—Drug interaction—Gefitinib—lung cancer	0.00524	0.0271	CcSEcCtD
Methotrimeprazine—CYP2D6—Doxorubicin—lung cancer	0.00407	0.0554	CbGbCtD
Methotrimeprazine—Sudden death—Irinotecan—lung cancer	0.00405	0.0209	CcSEcCtD
Methotrimeprazine—Drug interaction—Erlotinib—lung cancer	0.00313	0.0162	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Erlotinib—lung cancer	0.00291	0.015	CcSEcCtD
Methotrimeprazine—HTR2A—pulmonary artery—lung cancer	0.00288	0.113	CbGeAlD
Methotrimeprazine—Agranulocytosis—Pemetrexed—lung cancer	0.00255	0.0132	CcSEcCtD
Methotrimeprazine—Liver injury—Cisplatin—lung cancer	0.00224	0.0115	CcSEcCtD
Methotrimeprazine—Drug interaction—Gemcitabine—lung cancer	0.00218	0.0112	CcSEcCtD
Methotrimeprazine—Sudden death—Methotrexate—lung cancer	0.00202	0.0104	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Cisplatin—lung cancer	0.00188	0.00971	CcSEcCtD
Methotrimeprazine—Drug interaction—Paclitaxel—lung cancer	0.00182	0.0094	CcSEcCtD
Methotrimeprazine—Weight increased—Topotecan—lung cancer	0.00168	0.00866	CcSEcCtD
Methotrimeprazine—Constipation—Crizotinib—lung cancer	0.00163	0.00843	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Vinblastine—lung cancer	0.00158	0.00815	CcSEcCtD
Methotrimeprazine—Drug interaction—Docetaxel—lung cancer	0.00154	0.00797	CcSEcCtD
Methotrimeprazine—Constipation—Pemetrexed—lung cancer	0.00149	0.0077	CcSEcCtD
Methotrimeprazine—Constipation—Gefitinib—lung cancer	0.00148	0.00766	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Docetaxel—lung cancer	0.00143	0.00739	CcSEcCtD
Methotrimeprazine—Tachycardia—Teniposide—lung cancer	0.00138	0.00712	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Irinotecan—lung cancer	0.00137	0.00709	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Vinorelbine—lung cancer	0.00131	0.00677	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Pemetrexed—lung cancer	0.00129	0.00664	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Gefitinib—lung cancer	0.00128	0.0066	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Cisplatin—lung cancer	0.00125	0.00644	CcSEcCtD
Methotrimeprazine—CHRM5—epithelium—lung cancer	0.00122	0.048	CbGeAlD
Methotrimeprazine—Jaundice—Irinotecan—lung cancer	0.00113	0.00583	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Paclitaxel—lung cancer	0.00112	0.00578	CcSEcCtD
Methotrimeprazine—ADRA1D—epithelium—lung cancer	0.00109	0.0429	CbGeAlD
Methotrimeprazine—Liver injury—Doxorubicin—lung cancer	0.00106	0.00548	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Gemcitabine—lung cancer	0.00105	0.00544	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Teniposide—lung cancer	0.00104	0.00538	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Paclitaxel—lung cancer	0.000968	0.005	CcSEcCtD
Methotrimeprazine—Weight increased—Paclitaxel—lung cancer	0.000965	0.00498	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Docetaxel—lung cancer	0.00095	0.0049	CcSEcCtD
Methotrimeprazine—Jaundice—Etoposide—lung cancer	0.00094	0.00485	CcSEcCtD
Methotrimeprazine—Constipation—Vinblastine—lung cancer	0.000923	0.00476	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Etoposide—lung cancer	0.0009	0.00464	CcSEcCtD
Methotrimeprazine—Constipation—Topotecan—lung cancer	0.000896	0.00463	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Doxorubicin—lung cancer	0.000894	0.00462	CcSEcCtD
Methotrimeprazine—Constipation—Erlotinib—lung cancer	0.000887	0.00458	CcSEcCtD
Methotrimeprazine—Tachycardia—Vinorelbine—lung cancer	0.000875	0.00452	CcSEcCtD
Methotrimeprazine—Photosensitivity—Methotrexate—lung cancer	0.000854	0.00441	CcSEcCtD
Methotrimeprazine—Weight increased—Docetaxel—lung cancer	0.000818	0.00422	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Vinblastine—lung cancer	0.000795	0.0041	CcSEcCtD
Methotrimeprazine—Jaundice—Docetaxel—lung cancer	0.000781	0.00403	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Topotecan—lung cancer	0.000772	0.00399	CcSEcCtD
Methotrimeprazine—Constipation—Vinorelbine—lung cancer	0.000767	0.00396	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Docetaxel—lung cancer	0.000748	0.00386	CcSEcCtD
Methotrimeprazine—Photosensitivity—Doxorubicin—lung cancer	0.000739	0.00382	CcSEcCtD
Methotrimeprazine—DRD2—respiratory system—lung cancer	0.000735	0.0289	CbGeAlD
Methotrimeprazine—CHRM1—trachea—lung cancer	0.000675	0.0265	CbGeAlD
Methotrimeprazine—Hypersensitivity—Vinorelbine—lung cancer	0.000661	0.00341	CcSEcCtD
Methotrimeprazine—Somnolence—Irinotecan—lung cancer	0.000657	0.00339	CcSEcCtD
Methotrimeprazine—Tachycardia—Cisplatin—lung cancer	0.000655	0.00338	CcSEcCtD
Methotrimeprazine—Somnolence—Gemcitabine—lung cancer	0.00064	0.0033	CcSEcCtD
Methotrimeprazine—Constipation—Irinotecan—lung cancer	0.000632	0.00326	CcSEcCtD
Methotrimeprazine—ADRA1A—epithelium—lung cancer	0.000627	0.0247	CbGeAlD
Methotrimeprazine—CYP1A2—respiratory system—lung cancer	0.00062	0.0244	CbGeAlD
Methotrimeprazine—Constipation—Gemcitabine—lung cancer	0.000616	0.00318	CcSEcCtD
Methotrimeprazine—Tachycardia—Etoposide—lung cancer	0.0006	0.0031	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Doxorubicin—lung cancer	0.000593	0.00306	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methotrexate—lung cancer	0.000591	0.00305	CcSEcCtD
Methotrimeprazine—Tachycardia—Paclitaxel—lung cancer	0.000589	0.00304	CcSEcCtD
Methotrimeprazine—ADRA2C—bronchus—lung cancer	0.000588	0.0231	CbGeAlD
Methotrimeprazine—HRH1—respiratory system—lung cancer	0.000581	0.0228	CbGeAlD
Methotrimeprazine—Drowsiness—Methotrexate—lung cancer	0.000578	0.00298	CcSEcCtD
Methotrimeprazine—CYP2E1—respiratory system—lung cancer	0.000558	0.0219	CbGeAlD
Methotrimeprazine—Somnolence—Etoposide—lung cancer	0.000547	0.00282	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Irinotecan—lung cancer	0.000545	0.00281	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Methotrexate—lung cancer	0.000539	0.00278	CcSEcCtD
Methotrimeprazine—Somnolence—Paclitaxel—lung cancer	0.000536	0.00277	CcSEcCtD
Methotrimeprazine—ADRA2C—trachea—lung cancer	0.000528	0.0208	CbGeAlD
Methotrimeprazine—Constipation—Etoposide—lung cancer	0.000526	0.00271	CcSEcCtD
Methotrimeprazine—Constipation—Paclitaxel—lung cancer	0.000516	0.00266	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Doxorubicin—lung cancer	0.000512	0.00264	CcSEcCtD
Methotrimeprazine—Weight increased—Doxorubicin—lung cancer	0.000511	0.00263	CcSEcCtD
Methotrimeprazine—Drowsiness—Doxorubicin—lung cancer	0.0005	0.00258	CcSEcCtD
Methotrimeprazine—Tachycardia—Docetaxel—lung cancer	0.000499	0.00257	CcSEcCtD
Methotrimeprazine—ADRA2C—cardiac atrium—lung cancer	0.000496	0.0195	CbGeAlD
Methotrimeprazine—Hypersensitivity—Cisplatin—lung cancer	0.000495	0.00255	CcSEcCtD
Methotrimeprazine—Jaundice—Doxorubicin—lung cancer	0.000488	0.00252	CcSEcCtD
Methotrimeprazine—HRH1—epithelium—lung cancer	0.000485	0.0191	CbGeAlD
Methotrimeprazine—HTR2A—respiratory system—lung cancer	0.000485	0.0191	CbGeAlD
Methotrimeprazine—CHRM1—lung—lung cancer	0.000485	0.0191	CbGeAlD
Methotrimeprazine—Clomipramine—GSTP1—lung cancer	0.000475	0.142	CrCbGaD
Methotrimeprazine—ADRA2A—bronchus—lung cancer	0.000469	0.0185	CbGeAlD
Methotrimeprazine—Agranulocytosis—Doxorubicin—lung cancer	0.000467	0.00241	CcSEcCtD
Methotrimeprazine—Somnolence—Docetaxel—lung cancer	0.000454	0.00235	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Etoposide—lung cancer	0.000453	0.00234	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Paclitaxel—lung cancer	0.000444	0.00229	CcSEcCtD
Methotrimeprazine—Constipation—Docetaxel—lung cancer	0.000437	0.00226	CcSEcCtD
Methotrimeprazine—HRH1—trachea—lung cancer	0.000429	0.0169	CbGeAlD
Methotrimeprazine—ADRA2A—trachea—lung cancer	0.000422	0.0166	CbGeAlD
Methotrimeprazine—HTR2A—epithelium—lung cancer	0.000405	0.0159	CbGeAlD
Methotrimeprazine—ADRA2A—cardiac atrium—lung cancer	0.000396	0.0156	CbGeAlD
Methotrimeprazine—DRD2—lung—lung cancer	0.00039	0.0154	CbGeAlD
Methotrimeprazine—ADRA2C—lung—lung cancer	0.00038	0.0149	CbGeAlD
Methotrimeprazine—Hypersensitivity—Docetaxel—lung cancer	0.000377	0.00194	CcSEcCtD
Methotrimeprazine—HTR2A—trachea—lung cancer	0.000358	0.0141	CbGeAlD
Methotrimeprazine—CYP1A2—lung—lung cancer	0.000329	0.013	CbGeAlD
Methotrimeprazine—Somnolence—Methotrexate—lung cancer	0.000328	0.00169	CcSEcCtD
Methotrimeprazine—Tachycardia—Doxorubicin—lung cancer	0.000311	0.00161	CcSEcCtD
Methotrimeprazine—HRH1—lung—lung cancer	0.000308	0.0121	CbGeAlD
Methotrimeprazine—ADRA2A—lung—lung cancer	0.000303	0.0119	CbGeAlD
Methotrimeprazine—CYP2E1—lung—lung cancer	0.000296	0.0117	CbGeAlD
Methotrimeprazine—Somnolence—Doxorubicin—lung cancer	0.000284	0.00146	CcSEcCtD
Methotrimeprazine—Constipation—Doxorubicin—lung cancer	0.000273	0.00141	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methotrexate—lung cancer	0.000271	0.0014	CcSEcCtD
Methotrimeprazine—Fluphenazine—CYP2E1—lung cancer	0.000266	0.0796	CrCbGaD
Methotrimeprazine—ADRA2C—lymph node—lung cancer	0.00026	0.0102	CbGeAlD
Methotrimeprazine—HTR2A—lung—lung cancer	0.000258	0.0101	CbGeAlD
Methotrimeprazine—Hypersensitivity—Doxorubicin—lung cancer	0.000235	0.00121	CcSEcCtD
Methotrimeprazine—Thioridazine—CYP2E1—lung cancer	0.00023	0.0686	CrCbGaD
Methotrimeprazine—HRH1—lymph node—lung cancer	0.000211	0.00829	CbGeAlD
Methotrimeprazine—ADRA2A—lymph node—lung cancer	0.000207	0.00815	CbGeAlD
Methotrimeprazine—Diltiazem—ABCB1—lung cancer	0.000204	0.0609	CrCbGaD
Methotrimeprazine—Triflupromazine—ABCB1—lung cancer	0.000182	0.0543	CrCbGaD
Methotrimeprazine—Acepromazine—ALB—lung cancer	0.000176	0.0526	CrCbGaD
Methotrimeprazine—Thioproperazine—ALB—lung cancer	0.000172	0.0515	CrCbGaD
Methotrimeprazine—Pipotiazine—ALB—lung cancer	0.000169	0.0506	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP2E1—lung cancer	0.000167	0.05	CrCbGaD
Methotrimeprazine—Imipramine—CYP2E1—lung cancer	0.000166	0.0497	CrCbGaD
Methotrimeprazine—Fluphenazine—ABCB1—lung cancer	0.00014	0.0417	CrCbGaD
Methotrimeprazine—Clomipramine—ALB—lung cancer	0.000134	0.04	CrCbGaD
Methotrimeprazine—Clomipramine—ABCB1—lung cancer	0.000128	0.0382	CrCbGaD
Methotrimeprazine—Chlorprothixene—ABCB1—lung cancer	0.000127	0.038	CrCbGaD
Methotrimeprazine—Trimipramine—ABCB1—lung cancer	0.000118	0.0351	CrCbGaD
Methotrimeprazine—Promethazine—ABCB1—lung cancer	0.000113	0.0338	CrCbGaD
Methotrimeprazine—Trifluoperazine—ABCB1—lung cancer	0.000112	0.0334	CrCbGaD
Methotrimeprazine—Chlorpromazine—ALB—lung cancer	9.18e-05	0.0274	CrCbGaD
Methotrimeprazine—Chlorpromazine—ABCB1—lung cancer	8.76e-05	0.0262	CrCbGaD
Methotrimeprazine—Imipramine—ABCB1—lung cancer	8.72e-05	0.0261	CrCbGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—JUN—lung cancer	5.61e-06	2.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	5.6e-06	2.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	5.6e-06	2.7e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—lung cancer	5.58e-06	2.69e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MMP9—lung cancer	5.57e-06	2.69e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	5.57e-06	2.68e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MMP9—lung cancer	5.56e-06	2.68e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	5.55e-06	2.68e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—STAT3—lung cancer	5.55e-06	2.67e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MMP9—lung cancer	5.54e-06	2.67e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CDKN1A—lung cancer	5.54e-06	2.67e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PTEN—lung cancer	5.54e-06	2.67e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NRAS—lung cancer	5.54e-06	2.67e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTEN—lung cancer	5.53e-06	2.67e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PTEN—lung cancer	5.53e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MMP9—lung cancer	5.52e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CDKN1A—lung cancer	5.52e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—PIK3CA—lung cancer	5.52e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MYC—lung cancer	5.52e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	5.52e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PTEN—lung cancer	5.51e-06	2.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CDKN1A—lung cancer	5.5e-06	2.65e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—APOA1—lung cancer	5.5e-06	2.65e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CREBBP—lung cancer	5.5e-06	2.65e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—AKT1—lung cancer	5.49e-06	2.65e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PTEN—lung cancer	5.49e-06	2.65e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MMP9—lung cancer	5.47e-06	2.64e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—STAT3—lung cancer	5.46e-06	2.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MMP9—lung cancer	5.46e-06	2.63e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CDKN1A—lung cancer	5.45e-06	2.63e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK3—lung cancer	5.45e-06	2.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NRAS—lung cancer	5.45e-06	2.63e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTEN—lung cancer	5.44e-06	2.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	5.44e-06	2.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTEN—lung cancer	5.42e-06	2.61e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	5.41e-06	2.61e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HRAS—lung cancer	5.41e-06	2.61e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—AKT1—lung cancer	5.4e-06	2.6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EGFR—lung cancer	5.4e-06	2.6e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—AKT1—lung cancer	5.39e-06	2.6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—AKT1—lung cancer	5.38e-06	2.59e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EP300—lung cancer	5.37e-06	2.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CASP3—lung cancer	5.36e-06	2.59e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—AKT1—lung cancer	5.36e-06	2.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—lung cancer	5.36e-06	2.58e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—lung cancer	5.34e-06	2.57e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HRAS—lung cancer	5.33e-06	2.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—lung cancer	5.33e-06	2.57e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—AKT1—lung cancer	5.31e-06	2.56e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	5.3e-06	2.56e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MYC—lung cancer	5.3e-06	2.56e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	5.29e-06	2.55e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EP300—lung cancer	5.28e-06	2.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—EP300—lung cancer	5.28e-06	2.54e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EP300—lung cancer	5.27e-06	2.54e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.27e-06	2.54e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—PIK3CA—lung cancer	5.26e-06	2.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EP300—lung cancer	5.25e-06	2.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EP300—lung cancer	5.24e-06	2.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PIK3CA—lung cancer	5.23e-06	2.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCND1—lung cancer	5.22e-06	2.52e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—SRC—lung cancer	5.22e-06	2.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	5.22e-06	2.51e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CD—lung cancer	5.21e-06	2.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—JUN—lung cancer	5.21e-06	2.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	5.19e-06	2.5e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—PIK3CA—lung cancer	5.19e-06	2.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EP300—lung cancer	5.19e-06	2.5e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EGFR—lung cancer	5.19e-06	2.5e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—lung cancer	5.17e-06	2.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EP300—lung cancer	5.17e-06	2.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MYC—lung cancer	5.16e-06	2.49e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ALB—lung cancer	5.15e-06	2.48e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—SRC—lung cancer	5.14e-06	2.48e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—SRC—lung cancer	5.13e-06	2.47e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—SRC—lung cancer	5.11e-06	2.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HRAS—lung cancer	5.11e-06	2.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—lung cancer	5.1e-06	2.46e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—lung cancer	5.1e-06	2.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—SRC—lung cancer	5.09e-06	2.45e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—lung cancer	5.09e-06	2.45e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—lung cancer	5.09e-06	2.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MYC—lung cancer	5.07e-06	2.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MMP9—lung cancer	5.07e-06	2.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	5.05e-06	2.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—SRC—lung cancer	5.04e-06	2.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EGFR—lung cancer	5.04e-06	2.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTEN—lung cancer	5.04e-06	2.43e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—STAT3—lung cancer	5.04e-06	2.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—SRC—lung cancer	5.03e-06	2.42e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CG—lung cancer	5.02e-06	2.42e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NRAS—lung cancer	5.02e-06	2.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—lung cancer	5.02e-06	2.42e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—lung cancer	5.02e-06	2.42e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—lung cancer	5e-06	2.41e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—lung cancer	4.99e-06	2.41e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—lung cancer	4.98e-06	2.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EGFR—lung cancer	4.96e-06	2.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—lung cancer	4.96e-06	2.39e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—STAT3—lung cancer	4.95e-06	2.39e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—STAT3—lung cancer	4.94e-06	2.38e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NRAS—lung cancer	4.94e-06	2.38e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NRAS—lung cancer	4.93e-06	2.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—STAT3—lung cancer	4.93e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	4.92e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NRAS—lung cancer	4.92e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—lung cancer	4.91e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—STAT3—lung cancer	4.91e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NRAS—lung cancer	4.9e-06	2.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	4.9e-06	2.36e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—lung cancer	4.9e-06	2.36e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—lung cancer	4.89e-06	2.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HRAS—lung cancer	4.87e-06	2.35e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—STAT3—lung cancer	4.86e-06	2.34e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NRAS—lung cancer	4.85e-06	2.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—STAT3—lung cancer	4.85e-06	2.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NRAS—lung cancer	4.84e-06	2.33e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK3—lung cancer	4.81e-06	2.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EP300—lung cancer	4.81e-06	2.32e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HRAS—lung cancer	4.8e-06	2.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HRAS—lung cancer	4.8e-06	2.31e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—POMC—lung cancer	4.78e-06	2.31e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—AKT1—lung cancer	4.77e-06	2.3e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—lung cancer	4.76e-06	2.3e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK3—lung cancer	4.73e-06	2.28e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK3—lung cancer	4.72e-06	2.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—AKT1—lung cancer	4.71e-06	2.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK3—lung cancer	4.71e-06	2.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK3—lung cancer	4.69e-06	2.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—lung cancer	4.69e-06	2.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	4.69e-06	2.26e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MYC—lung cancer	4.68e-06	2.25e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SRC—lung cancer	4.67e-06	2.25e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CREBBP—lung cancer	4.66e-06	2.25e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—lung cancer	4.66e-06	2.25e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK3—lung cancer	4.65e-06	2.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	4.63e-06	2.23e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PIK3CA—lung cancer	4.63e-06	2.23e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MYC—lung cancer	4.6e-06	2.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—lung cancer	4.6e-06	2.22e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—lung cancer	4.6e-06	2.22e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MYC—lung cancer	4.59e-06	2.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MYC—lung cancer	4.58e-06	2.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EGFR—lung cancer	4.58e-06	2.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MYC—lung cancer	4.56e-06	2.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	4.55e-06	2.19e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CB—lung cancer	4.55e-06	2.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—lung cancer	4.53e-06	2.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MYC—lung cancer	4.52e-06	2.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—AKT1—lung cancer	4.51e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MYC—lung cancer	4.51e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—STAT3—lung cancer	4.51e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTGS2—lung cancer	4.5e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EGFR—lung cancer	4.5e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	4.5e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NRAS—lung cancer	4.5e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EGFR—lung cancer	4.49e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EGFR—lung cancer	4.48e-06	2.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EGFR—lung cancer	4.46e-06	2.15e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EGFR—lung cancer	4.42e-06	2.13e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CD—lung cancer	4.42e-06	2.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EGFR—lung cancer	4.41e-06	2.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	4.38e-06	2.11e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ALB—lung cancer	4.36e-06	2.1e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—lung cancer	4.35e-06	2.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRAS—lung cancer	4.34e-06	2.09e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—lung cancer	4.32e-06	2.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	4.31e-06	2.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	4.31e-06	2.08e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—AKT1—lung cancer	4.3e-06	2.07e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—AKT1—lung cancer	4.28e-06	2.06e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—lung cancer	4.25e-06	2.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PIK3CA—lung cancer	4.25e-06	2.05e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—lung cancer	4.24e-06	2.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—AKT1—lung cancer	4.24e-06	2.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—AKT1—lung cancer	4.24e-06	2.04e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—lung cancer	4.23e-06	2.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—lung cancer	4.23e-06	2.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—lung cancer	4.22e-06	2.03e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MYC—lung cancer	4.19e-06	2.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—lung cancer	4.18e-06	2.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—lung cancer	4.17e-06	2.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—lung cancer	4.16e-06	2.01e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRAS—lung cancer	4.16e-06	2.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—lung cancer	4.15e-06	2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EGFR—lung cancer	4.1e-06	1.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRAS—lung cancer	4.05e-06	1.95e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRAS—lung cancer	3.99e-06	1.92e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—lung cancer	3.99e-06	1.92e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PIK3CA—lung cancer	3.97e-06	1.91e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTEN—lung cancer	3.93e-06	1.89e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	3.91e-06	1.88e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PIK3CA—lung cancer	3.9e-06	1.88e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PIK3CA—lung cancer	3.9e-06	1.88e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PIK3CA—lung cancer	3.89e-06	1.87e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—lung cancer	3.88e-06	1.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PIK3CA—lung cancer	3.87e-06	1.87e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—lung cancer	3.87e-06	1.87e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CB—lung cancer	3.85e-06	1.86e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—lung cancer	3.84e-06	1.85e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PIK3CA—lung cancer	3.84e-06	1.85e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—AKT1—lung cancer	3.83e-06	1.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	3.83e-06	1.84e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTGS2—lung cancer	3.82e-06	1.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—lung cancer	3.81e-06	1.84e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—AKT1—lung cancer	3.79e-06	1.82e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—lung cancer	3.78e-06	1.82e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—lung cancer	3.77e-06	1.82e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—lung cancer	3.76e-06	1.81e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—lung cancer	3.75e-06	1.81e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—EP300—lung cancer	3.75e-06	1.81e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—lung cancer	3.71e-06	1.79e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—lung cancer	3.7e-06	1.78e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—AKT1—lung cancer	3.68e-06	1.77e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRAS—lung cancer	3.67e-06	1.77e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRAS—lung cancer	3.62e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRAS—lung cancer	3.61e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRAS—lung cancer	3.6e-06	1.73e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRAS—lung cancer	3.58e-06	1.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—AKT1—lung cancer	3.58e-06	1.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	3.56e-06	1.71e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRAS—lung cancer	3.55e-06	1.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRAS—lung cancer	3.54e-06	1.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—AKT1—lung cancer	3.52e-06	1.7e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—lung cancer	3.52e-06	1.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—AKT1—lung cancer	3.47e-06	1.67e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—lung cancer	3.46e-06	1.67e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—lung cancer	3.45e-06	1.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—lung cancer	3.44e-06	1.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—lung cancer	3.44e-06	1.66e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—lung cancer	3.43e-06	1.65e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—lung cancer	3.4e-06	1.64e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—lung cancer	3.39e-06	1.63e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTEN—lung cancer	3.33e-06	1.6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRAS—lung cancer	3.29e-06	1.59e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—AKT1—lung cancer	3.24e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—AKT1—lung cancer	3.19e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—AKT1—lung cancer	3.19e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—AKT1—lung cancer	3.19e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—AKT1—lung cancer	3.18e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—EP300—lung cancer	3.17e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—AKT1—lung cancer	3.17e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—lung cancer	3.15e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—AKT1—lung cancer	3.13e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—AKT1—lung cancer	3.13e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.9e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CA—lung cancer	2.77e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CA—lung cancer	2.35e-06	1.13e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—AKT1—lung cancer	2.26e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—AKT1—lung cancer	1.92e-06	9.24e-06	CbGpPWpGaD
